H. Miles Prince

Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma

Meletios Α. Dimopoulos, Andrew Spencer, Michael Attal et al. · New England Journal of Medicine · 2007 · 1.5K citations

Medicine, Pharmacology, Pharmacotherapy +14

Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

Richard Piekarz, Robin Frye, Maria L. Turner et al. · Journal of Clinical Oncology · 2009 · 737 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy

Bertrand Coiffier, Barbara Pro, H. Miles Prince et al. · Journal of Clinical Oncology · 2012 · 674 citations

Medicine, Pharmacology, Pharmacotherapy +13

Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer

Elise A. Olsen, Sean Whittaker, Youn H. Kim et al. · Journal of Clinical Oncology · 2011 · 658 citations · Full text

Medicine, Dermatology, Oncology +17

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

Michel Attal, Paul G. Richardson, S. Vincent Rajkumar et al. · The Lancet · 2019 · 636 citations

Medicine, Hematology, Pharmacotherapy +15